Best The Uromigos Podcasts (2024)

Eric Jonasch, Co-Chair of the NCCN RCC Guidelines, gives insight into the process of guideline modification and discusses updates in adjuvant, front-line and refractory RCC

1
Episode 336: Which patients are not suitable for 1st line EVP in bladder cancer 35:35

Play Pause

29m ago35:35

35:35

Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects.

1
Episode 335: Novel immune therapies for renal cancer 37:31

22h ago37:31

37:31

David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.

1
Episodio 334 en español: Tres Uramigas ASCO 2024 36:33

2d ago36:33

36:33

Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata

1
Episode 333: The Uromigos Cup - The Netherlands 26:20

19d ago26:20

26:20

Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions

1
Episode 332: The Uromigos Cup - Germany's Entry 35:55

2M ago35:55

35:55

Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football

1
Episode 331: AUA 2024 NMIBC Highlights 33:56

2M ago33:56

33:56

Aditya Bagrodia describes three new drugs/studies in NMIBC.

1
Episode 330: ASCO 2024 Highlights 52:47

2M ago52:47

52:47

Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.

1
Episode 329: Japan in the Uromigos Cup qualifying round 30:48

2M ago30:48

30:48

Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.

1
Episode 328 ASCO24: Emergency podcast - what the NADINA trial means for preoperative GU cancer studies 26:32

2M ago26:32

26:32

David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.

1
Episode 327 ASCO24: CM901 and EV302 Efficacy and QOL Updates 24:02

2M ago24:02

24:02

Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.

1
Episode 326 ASCO24: KIM-1 in Renal Cancer 18:08

2M ago18:08

18:08

Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.

1
Episode 325 ASCO24: KN426 and the CLEAR trial - tissue based biomarkers for kidney cancer 33:44

2M ago33:44

33:44

Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.

1
Episode 324 ASCO24: SURE1 neoadjuvant sacituzumab govitecan in UC 20:43

2M ago20:43

20:43

Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.

1
Episode 323 ASCO24: TDXD in Bladder Cancer 29:47

2M ago29:47

29:47

Jonathan Rosenberg gets to grips with the data available for the bladder cohort from the TDXD Destiny pan-tumour cohort.

1
Episode 322 ASCO24: The role of ctDNA in the TheraP trial (LuPSMA vs cabazitaxel in CRPC) 22:16

2M ago22:16

22:16

Alex Wyatt describes the predictive resistance of ctDNA fraction at baseline in predicting outcome.

1
Episode 321 ASCO24: CHAARTED-2 in prostate cancer - is the sequel as good as the original? 23:25

2M ago23:25

23:25

Christos Kyriakopoulos describes the outcome of this study, where cabazitaxel with abiraterone as combined with abiraterone alone in docetaxel refractory CRPC.

1
Episode 320: Team Canada's entry for the Uromigos Cup 23:30

3M ago23:30

23:30

Danny Heng, Christian Kollmannsberger and Kala Sridhar answer questions in an attempt to get to Nashville and take on LA to win the Uromigos Cup.

1
Episode 319: ASCO 2024: A Preview of GU Data 33:49

3M ago33:49

33:49

What to see at the ASCO 2024 Annual Meeting, with Silke Gillessen.

1
Episode 318: The Lancet Commission on prostate cancer: planning for a surge in cases 31:59

3M ago31:59

31:59

Nick James discusses this paper, which covers broad issues in prostate cancer - including diagnosis and treatment with a focus on the future.

1
Episode 317: AUA 2024 Preview with the AUA Secretary 22:16

3M ago22:16

22:16

David Penson discusses highlights for the upcoming meeting. He articulates his excitement around the NMIBC data.

1
Episode 316: APCCC 2024 Summary with Silke Gillessen 41:11

4M ago41:11

41:11

Silke covers key aspects of the meeting, including surgery vs RT, genetic and somatic testing, PSMA imaging and 1st line triplet therapy.

1
Episode 315: APCCC 2024 Quickfire - Bone health, hot flashes and gynecomastia in prostate cancer 18:17

4M ago18:17

18:17

Chris Sweeney is joined by Matt Smith, Anthony Joshua and Lisa Horvath to discuss the management of these complex issues in advanced prostate cancer.

1
Episode 314: APCCC 2024 Cardiovascular risks with hormone therapy in prostate cancer 25:15

4M ago25:15

25:15

Thomas Suter and Chuck Ryan discuss identification and management of cardiovascular disease for patients starting therapy for prostate cancer.

1
Episode 313: APCCC 2024 Debate - Radiation therapy in advanced disease 35:40

4M ago35:40

35:40

Thomas Zilli and Pierre Blanchard discuss this topic from Lugano.

1
Episode 312: APCCC 2024 Radiation therapy after surgery for prostate cancer 23:56

4M ago23:56

23:56

Jason Efstathiou and Piet Ost discuss the data for and against this approach.

1
Episode 311: The Uromigos Paper of the Month - The POUT Trial 36:02

4M ago36:02

36:02

Alison Birtle describes adjuvant chemotherapy in bladder cancer.

1
Episode 310: Dosing and duration of drugs from a cost perspective 28:28

4M ago28:28

28:28

Daniel Goldstein describes his work on this issue.

1
Episode 309: EAU24 Checkmate 274 - OS for adjuvant nivolumab in bladder cancer 27:13

4M ago27:13

27:13

In this second part, Matt Galsky describes the OS signal data. We also look into the future.

1
Episode 308: EAU24 IMVIGOR 011 - Outcome of ctDNA negative patients post-cystectomy 23:09

4M ago23:09

23:09

Tom, Brian and Matt Galsky review the screening component of this study, presented at EAU24.

1
Episode 307: Bladder-Sparing Approaches Part 2 35:14

4M ago35:14

35:14

Michiel Van der Heijden explores the role of radiotherapy and other neoadjuvant and other neoadjuvant combinations to prevent the need for surgery.

1
Episode 306: The Uromigos Paper of the Month - Chemo/Nivo as a bladder sparing approach in UC 29:56

5M ago29:56

29:56

Matt Galsky describes his phase 2 study looking at gem/cis/nivo followed by nivo in responders. This potentially avoids cystectomy.

1
Episode 305: FDA and Oncology Clinical Trials 29:35

5M ago29:35

29:35

FDA Deputy Oncology Director Dan Suzman described approaches to oncology trials. Tom asks 3 last questions which annoys Brian more than usual.

1
Episode 304: A PSMA CD3 Bispecific T-cell Engager in CRPC 30:43

5M ago30:43

30:43

Tanya Dorff describes acapatamab, a prostate-specific membrane antigen (PSMA) CD3 bispecific engager.

1
Episode 303: Community GU Oncology 24:16

5M ago24:16

24:16

Michael Lattanzi discusses treatment plans and research in the community.

1
Episode 302: Part 2- Adjuvant Therapy in solid tumors 34:37

6M ago34:37

34:37

Hans Hammers discusses trial design and patient selection in the adjuvant setting.

1
Episode 301: Cancer research from a global perspective. 31:06

6M ago31:06

31:06

Vania Wisdom, editor of the Lancet, talks about approaches to cancer treatment and research in developing countries

1
Episode 300: Adjuvant PD1 Therapy in Solid Tumours 42:15

6M ago42:15

42:15

David McDermott discusses melanoma and renal data. We never get to bladder or lung.

1
Episode 299: Androgen receptor ligand-directed degrader BMS-986365 36:40

6M ago36:40

36:40

Dana Rathkopf describes phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer

1
Episode 298: ASCO GU 2024 Highlights 27:15

6M ago27:15

27:15

Silke, Tom and Brian cover the bases.

1
Episode 297: ASCO GU 2024: CONTACT2 Part 2 - The Aftermath 22:46

6M ago22:46

22:46

Neeraj Agarwal addresses the issues raised at the meeting.

1
Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan 23:58

7M ago23:58

23:58

Cris Bergerot describes her modifications of existing QOL models while Tom describes the QOL data from LS005

1
Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer 32:46

7M ago32:46

32:46

Pedro Barata summarises his ASCO GU discussion on this topic.

1
Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer 33:17

7M ago33:17

33:17

Andrea Apolo describes the results of this positive trial.

1
Episode 293: ASCO GU 2024: BRCAaway and CONTACT2 22:21

7M ago22:21

22:21

Kim Chi discussed the prostate cancer oral session at ASCO GU 2024.

1
Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer 26:04

7M ago26:04

26:04

Misha Beltran describes the activity of this novel agent in neuroendocrine prostate cancer.

1
Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer 31:15

7M ago31:15

31:15

Neeraj Agarwal describes the results of this positive randomised Phase 3 trial.

1
Episode 290: ASCO GU 2024 Preview 26:58

7M ago26:58

26:58

What to look out for in bladder, prostate and renal cancer at this year's meeting.

Podcasts Worth a Listen

The Uromigos Podcasts

Podcasts Worth a Listen

Quick Reference Guide